Dr. Mark Wardle MB BCh MD FRCP FBCS

Employment / roles

Past employment

Qualifications and prizes

  • Fellow of the British Computer Society (FBCS), 2024-
  • NHS Wales Awards Winner 2019 - South East Wales MND network
  • Founding Fellow, Faculty of Clinical Informatics, 2018-
  • Fellowship of the Royal College of Physicians (FRCP), 2015-
  • Doctorate of Medicine (MD), Cardiff University, 2009 - Cerebellar ataxia: A clinical and genetic study in South Wales
  • Sir Charles Symonds Prize, Association of British Neurologists, Best Platform Presentation, 2007
  • Membership of the Royal College of Physicians (MRCP), 2004
  • MB BCh, University of Wales College of Medicine, 1999
  • Elizabeth Pipe Prize in Paediatrics, 1999


  • Gray L et al. NIHSCR Wales BRAIN unit, £1,499,910 July 2015-
  • Bisson J et al. Biobanking Research support, NIHSCR AHSC, £130,322, Apr 2012-Mar 2015

Roles and responsibilities


  • General neurology, University Hospital Wales and Prince Charles Hospital 2011-
    • Two clinics per week
    • Two ward referral sessions per week
    • On-call for neurology and stroke thrombolysis
  • Specialist ataxia and movement disorders clinic, Cardiff and Vale 2011-
    • One clinic per week
  • Specialist motor neurone disease clinic: Prince Charles Hospital 2012-
    • One clinic per month
  • Clinical lead for IT for Welsh Clinical Portal project, Cardiff and Vale 2011-2015
  • Educational and clinical supervisor, Wales Deanery 2011-
  • Medical expert for Court of Protection, December 2015


  • Shortlisting and judge, COVID-19 digital solutions fund, 2020
  • Member, “Digital transformation panel”, Welsh Assembly Government, 2018 (“System reboot” report)
  • Designer and clinical lead for COM2 project, Cardiff and Vale University Health Board providing outpatient management and SNOMED CT functionality
  • Shortlisting and judge, Intel AI grant, 2019
  • NHS Wales Architecture Review Advisory Group, 2019
  • Interviewed by Wired magazine on privacy and artificial intelligence in healthcare
  • Member, Clinical Content subcommittee, Apperta Foundation, 2017-2018
  • Member, “Once for Wales” Task and Finish Group, Welsh Assembly Government, 2017-2018
  • Information standards, Task and finish group, 2016-2017.
  • Member, Welsh Clinical Informatics Council, NHS Wales Informatics Service, 2015-
  • Co-director, South Wales Motor Neurone Disease Network, 2015-
  • National UK MND register steering group, 2015-
  • Clinical databases lead, NISCHR BRAIN unit, 2015-
  • Association of British Neurologists Neurogenetics Advisory Group, 2015-2018
  • Wales Neuromuscular network steering group, 2013-
  • Medical Schools Council Assessment Alliance (MSA-AA) reference group 2012-2016
  • Ataxia UK, medical advisory panel, 2012-
  • Clinical advisor, Welsh Neurosciences Research Tissue Bank (WNRTB), 2012-

Publications and abstracts


  • Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis K Harding, O Williams, M Willis, et al. JAMA neurology 76 (5), 536-541 57 2019

  • Socioeconomic status and disability progression in multiple sclerosis: a multinational study KE Harding, M Wardle, R Carruthers, et al. Neurology 92 (13), e1497-e1506 18 2019

  • A Case of Treatment Resistance and Complications in a Patient with Stiff Person Syndrome and Cerebellar Ataxia LA Jones, W Baber, M Wardle, et al. Tremor and Other Hyperkinetic Movements 9 2019

  • Carroll LS, Massey TH, Wardle M, Peall KJ. Dentatorubral-pallidoluysian Atrophy: An Update. Tremor Other Hyperkinet Mov (N Y). 2018 Oct 1;8:577. doi: 10.7916/D81N9HST. PMID: 30410817; PMCID: PMC6222020.

  • K Harding, V Anderson, O Williams, M Willis, S Butterworth, E Tallantyre. A contemporary study of mortality in the multiple sclerosis population of south east Wales. Multiple sclerosis and related disorders, 2018; 25, 186-191

  • M Kopczynska, WM Zelek, S Vespa et al. Complement System Biomarkers in Epilepsy. Seizure-European Journal of Epilepsy 2018

  • MO Alsaeed, KE Harding, OH Williams, MD Willis, J Hrastelj et al. Multiple sclerosis: Long‐term outcomes in ethnic minorities with MS: analysis of a UK population‐based registry. European Journal of Neurology 1 2018

  • van de Zande NA, Massey TH, McLauchlan D, Pryce-Roberts A, Zutt R, Wardle M, Payne G, Clenaghan C, Tijssen MAJ, Rosser AE, Peall KJ. Clinical Characterisation of Dystonia in Patients with Huntington’s Disease. Eur J Neurol, 2017 [in press]

  • Harding K, Tilling K, MacIver C, Willis M, Joseph F, Ingram G, Hirst C, Wardle M, Pickersgill TP, Robertson NP. Seasonal variation in multiple sclerosis relapse. J Neurol, 2017. doi:10.1007/s00415-017-8485-0

  • Wardle M and Spencer A. Implementation of SNOMED CT in an online clinical database. Future Hosp J June 1, 2017 vol. 4 no. 2 126-130.

  • Williams OH, Harding K, Rimmer A et al. Disease Modifying Treatments in MS: Clinical Outcomes of Induction and Escalation Strategies. MULTIPLE SCLEROSIS JOURNAL 2017:23 (2), 316-316.

  • Harding KH, Williams OH, Willis MD et al. Socioeconomic Status and Disability in Multiple Sclerosis. MULTIPLE SCLEROSIS JOURNAL 23 (2), 322-322.

  • Willis MD, Harding KE, Pickersgill TP, Wardle M, Pearson OR, Scolding NJ, Smee J, Robertson NP. Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort. Mult Scler. 2016 Aug;22(9):1215-23. doi: 10.1177/1352458515614092.

  • Wardle M, Sadler M How to set up a clinical database Practical Neurology 2016;16:70-74.

  • Tallantyre EC, Wardle M, Robertson NP How to run a multiple sclerosis relapse clinic Practical Neurology 2016;16:62-69.

  • Willis MD, Harding KE, Wardle M et al Site-specific clinical disease onset in multiple sclerosis. Eur J Neurol. 2015 Apr;22(4):732-5. doi: 10.1111/ene.12564. Epub 2014 Sep 8.

  • Peall KJ, Kurian MA, Wardle M et al. SGCE and myoclonus dystonia: motor characteristics, diagnostic criteria and clinical predictors of genotype. J Neurol. 2014 Dec;261(12):2296-304. doi: 10.1007/s00415-014-7488-3. Epub 2014 Sep 11.

  • Harding KE, Wardle M, Moore P, Tomassini V, Pickersgill T, Ben-Shlomo Y, Robertson NP (2014). Modelling the natural history of primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2014 May 14. pii: jnnp-2014-307791.

  • Peall KJ, Smith DJ, Kurian MA, Wardle M et al SGCE mutations cause psychiatric disorders: clinical and genetic characterization. Brain. 2013 Jan;136(Pt 1):294-303.

  • Moore P, Harding KE, Clarkson H, Pickersgill TP, Wardle M, Robertson NP (2013). Demographic and clinical factors associated with changes in employment in multiple sclerosis. Mult Scler. 2013 Oct;19(12):1647-54.

  • Fawcett K, Mehrabian M, Liu YT, Hamed S, Elahi E, Revesz T, Koutsis G, Herscheson J, Schottlaender L, Wardle M, Morrison PJ, Morris HR, Giunti P, Wood N, Houlden H (2013) “The frequency of spinocerebellar ataxia type 23 in a UK population.” J Neurol. 2013 Mar;260(3):856-9. doi: 10.1007/s00415-012-6721-1. Epub 2012 Oct 30. Erratum in: J Neurol. 2013 Mar;260(3):860.

  • Harding KE, Liang K, Cossburn MD, Ingram G, Hirst CL, Pickersgill TP, Te Water Naude J, Wardle M, Ben-Shlomo Y, Robertson NP (2013) “Long-term outcome of paediatric-onset multiple sclerosis: a population-based study.” J Neurol Neurosurg Psychiatry. 2013 Feb;84(2):141-7. doi: 10.1136/jnnp-2012-303996. Epub 2012 Nov 15.

  • Becker EB, Zuliani L, Pettingill R, Lang B, Waters P, Dulneva A, Sobott F, Wardle M, Graus F, Bataller L, Robertson NP, Vincent A (2012) “Contactin-associated protein-2 antibodies in non-paraneoplastic cerebellar ataxia.” J Neurol Neurosurg Psychiatry. 2012 Apr;83(4):437-40. doi: 10.1136/jnnp-2011-301506. Epub 2012 Feb 15.

  • Wardle, M.; Morris H.; Robertson, N. (2009), ‘Clinical and genetic characteristics of non-Asian dentatorubral pallidoluysian atrophy: A systematic review’. Mov Disord 24(11):1636-40.

  • Wardle, M. (2009), ‘Cerebellar ataxia: A clinical and genetic study in South Wales’, MD thesis, Cardiff University.

  • Wardle, M.; Majounie, E.; Muzaimi, M.; Williams, N.; Morris, H. & Robertson, N. (2009), ‘The genetic aetiology of chronic progressive cerebellar ataxia: a population-based study’, J Neurol 256 (3):343-8. Epub 2009 Mar 6.

  • Wardle, M.; Majounie, E.; Williams, N.; Rosser, A.; Morris, H. & Robertson, N. (2008), ‘Dentatorubral pallidoluysian atrophy in South Wales’, J Neurol Neurosurg Psychiatry 79, 804-807.

  • Majounie, E.; Wardle, M.; Muzaimi, M.; Cross, W.; Robertson, N. P.; Williams, N. & Morris, H. (2007), ‘Case control analysis of repeat expansion size in ataxia.’, Neurosci Lett 429, 28-32.

  • Wardle, M. & Robertson, N. (2007), ‘Progressive late-onset cerebellar ataxia’, ACNR 7, 6-12.

Published abstracts

  • T Saad, K Dawson, C Hirst, I Baker, A Lowman, M Wardle, K Harding Epidemiology of motor neurone disease in wales Journal of Neurology, Neurosurgery and Psychiatry 90 (12), e58

  • K Harding, E Kingwell, M Wardle, F Zhu, N Robertson, H Tremlett Socioeconomic status and progression of disability in MS J Neurol Neurosurg Psychiatry 2018 89 (10), A21-A21

  • M Alsaeed, K Harding, M Willis, E Tallantyre, M Wardle, T Pickersgill et al. Poster 1151: Ethnic minority outcomes in multiple sclerosis J Neurol Neurosurg Psychiatry 2017;88 (Suppl 1), A2-A2

  • WO Pickrell, S Ahmed, SF Halpin, M Wardle, K Hamandi. Poster 0018 Two cases of subarachnoid haemorrhage caused by venous sinus thrombosis J Neurol Neurosurg Psychiatry 2017; 88 (Suppl 1), A17-A17

  • B. Mohamed, E.L. Lane, E.C. Thomas, M. Landwehr, C.W. Ngu, J. Butler, K. Williams, M. Wardle. iPad-based preassessment questionnaires are feasible in a Parkinson’s service [abstract]. Mov Disord. 2016; 31 (suppl 2).

  • Harding K, Williams O, Willis M, Wardle M, Pickersgill T, Robertson NP. CONTEMPORARY ANALYSIS OF MORTALITY IN MULTIPLE SCLEROSIS J Neurol Neurosurg Psychiatry 2016;87:e1.

  • Healy S, Nasser T, Willis M, et al THYROID AUTOIMMUNITY FOLLOWING ALEMTUZUMAB TREATMENT FOR MS J Neurol Neurosurg Psychiatry 2016;87:e1.

  • DISEASE MODIFYING TREATMENTS IN MS: INDUCTION OR ESCALATION? Owain H Williams, Katharine E Harding, Mark Willis, Trevor Pickersgill, Mark Wardle, Neil P Robertson J Neurol Neurosurg Psychiatry 2015;86:11 e4 doi:10.1136/jnnp-2015-312379.29

  • DISEASE MODIFYING TREATMENT UTILISATION IN MULTIPLE SCLEROSIS Owain H Williams, Katharine E Harding, Mark Willis, Trevor Pickersgill, Mark Wardle, Neil P Robertson. J Neurol Neurosurg Psychiatry 2015;86:11 e4 doi:10.1136/jnnp-2015-312379.125

  • Clinical characteristics and genetic testing of a Huntingtin mutation negative cohort [abstract]. Peall, K.J., Morris, H.R., Wardle, M.; Movement Disorders 2015;30 Suppl 1 :362

  • FACTORS ASSOCIATED WITH EMERGENCY ATTENDANCES FOR EPILEPSY Lynch EC, Lacey AS, Pickrell WO, Smith PEM, Wardle M. J Neurol Neurosurg Psychiatry 2014;85:10. doi:10.1136/jnnp-2014-309236.73

  • NO TEMPORAL EFFECT ON DISABILITY IN MULTIPLE SCLEROSIS Katharine Harding, Mark Willis, Mark Wardle, Trevor Pickersgill, Neil Robertson J Neurol Neurosurg Psychiatry 2014;85:10 e4 doi:10.1136/jnnp-2014-309236.10

  • ALEMTUZUMAB: LONG TERM FOLLOW-UP IN A SINGLE CENTRE COHORT Mark Willis, Katharine Harding, Mark Wardle et al. J Neurol Neurosurg Psychiatry 2014;85:10 e4 doi:10.1136/jnnp-2014-309236.8

  • LATE–ONSET MULTIPLE SCLEROSIS IN SOUTH–EAST WALES Katharine Harding, Megan Griffiths, Mark Wardle, Valentina Tomassini, Trevor Pickersgill, Neil Robertson J Neurol Neurosurg Psychiatry 2013;84:11 e2 doi:10.1136/jnnp-2013-306573.26

  • EPISTATIC EFFECTS ON THE PHENOTYPE OF MULTIPLE SCLEROSIS Harding K, Loveless S, Wardle M et al J Neurol Neurosurg Psychiatry 2013;84:11 e2

  • Neighbourhood socioeconomic status and multiple sclerosis: the impact of area level deprivation on multiple sclerosis risk frequency and disease progression Moore P, Harding K, Wardle M, Pickersgill TP, Robertson NP. Mult Scler, October 2013; vol. 19, 11 suppl: pp. 74-558.

  • ARE PSYCHIATRIC SYMPTOMS A CORE PHENOTYPE OF MYOCLONUS DYSTONIA SYNDROME CAUSED BY SGCE MUTATIONS? KJ Peall, DJ Smith, MA Kurian, M Wardle et al J Neurol Neurosurg Psychiatry 2013;84:9 e1 doi:10.1136/jnnp-2013-306103.24

  • IL-7, IL-9 and IL-12 are associated with current aspects of disease, but do not predict disease course in multiple sclerosis Harding, KE; Cossburn, MD; Moore, P; Pickersgill, TP; Wardle, M; Robertson, NP. MULTIPLE SCLEROSIS JOURNAL 18;117-117 Supplement: 4.OCT 2012

  • Acute Stroke Thrombolysis-a Welsh centre’s perspective QTH Anjum, HGM Shetty, A Reed, TAT Hughes, PE Smith, T Pickersgill et al CEREBROVASCULAR DISEASES 35, 676-676

  • DO AGE AT ONSET OR GENDER AFFECT ACCUMULATION OF DISABILITY IN PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS? K Harding, L Curzon, P Moore, MD Cossburn, G Ingram, TP Pickersgill, M Wardle, NP Robertson J Neurol Neurosurg Psychiatry 2012;83:Suppl 2 A35

  • REVERSIBLE CEREBRAL VASOCONSTRICTION SYNDROME AS A CAUSE OF SUBARACHNOID HAEMORRHAGE K Ali, Y Joshi, S Halpin, M Wardle J Neurol Neurosurg Psychiatry 2012;83:Suppl 2 A1 doi:10.1136/jnnp-2012-304200a.1

  • ‘Late onset cerebellar ataxia: natural history and prognosis’, Wardle, M.; Muzaimi, M.; Robertson, N. J Neurol Neurosurg Psychiatry 2008 80,97-128

  • ‘DRPLA in South Wales’, Wardle, M.; Majounie, E.; Williams, N.; Rosser, A.; Morris, H. & Robertson, N. J Neurol Neurosurg Psychiatry 2007;78, 1014-1038.